Phase 2 Stomach Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have chosen to take part and have signed a consent form
• People aged 18 to 75 years old
• People who have been confirmed by a pathology test to have stomach (gastric) cancer or cancer at the junction where the stomach meets the oesophagus (gastroesophageal junction)
• People whose cancer is at a certain stage — specifically, where the tumour has grown into the stomach wall or nearby tissue, and/or has spread to nearby lymph nodes, but not to distant parts of the body — and where scans and a keyhole procedure have shown the cancer can be fully removed by surgery
• People who have not yet received any cancer treatment, such as surgery, radiation, chemotherapy, targeted therapy, or immunotherapy
• People who are planned to have surgery after completing the pre-surgery treatment used in this trial
• People who are able to swallow tablets normally
• People who are in good general physical condition, rated 0 or 1 on a standard health performance scale (confirm with trial site)
• People expected to live at least 12 months
• People whose blood test results meet the required levels — including white blood cell count, platelet count, and haemoglobin — without recent use of blood transfusions or certain blood-stimulating medications
• People whose liver and kidney function blood test results are within the required ranges
• Women of childbearing age who have a negative pregnancy test within 7 days before the first dose and who agree to use highly effective contraception during the trial and for 120 days after the last dose
• Men with partners who could become pregnant who are either surgically sterilised or agree to use highly effective contraception during the trial and for 120 days after the last dose

Who may not be able to join:

• People whose cancer cannot be fully removed by surgery, either due to the nature of the tumour, other health reasons, or personal refusal of surgery
• People who have had, or currently have, another type of cancer
• People living with a serious ongoing illness that is considered too risky to manage during treatment, such as severe heart disease, uncontrolled high blood pressure, or significant liver or kidney problems
• People who have had a hole in the digestive tract (perforation), an abdominal abscess, or a bowel blockage within the past 3 months, or whose scans or symptoms suggest a current bowel blockage
• People who have had significant bleeding — such as bleeding from the stomach or digestive tract, a bleeding stomach ulcer, or inflamed blood vessels — within 3 months before starting the study drug (certain additional tests may be required if stool tests show traces of blood)
• People who currently have an active infection requiring treatment with antibiotics, antiviral, or antifungal medications
• People with active hepatitis B or hepatitis C, as defined by specific virus levels in the blood (confirm with trial site)
• People with an immune system condition present from birth or developed over time, such as HIV infection
• People with an active autoimmune disease, or a history of autoimmune disease that could come back
• People who are planned for, or have previously had, an organ transplant or a bone marrow transplant using donor cells
• People with current or past lung inflammation or scarring (interstitial lung disease) that required steroid treatment, or who have active pneumonia or severely reduced lung function shown on a screening scan; people with active tuberculosis
• People currently taking, or recently treated with, medications that suppress the immune system, including steroid medications used for this purpose
• People who have received a live vaccine within 28 days before starting the study drug, or who would need such a vaccine during treatment or within 60 days after the last dose
• People who are known to be allergic to any of the medications or their ingredients used in this trial
• People who are currently breastfeeding
• People who, in the opinion of the trial doctor, have any other factor that could affect their safety or require them to leave the study

Important: Always verify eligibility with the trial site directly before applying.